Log in

NASDAQ:APENApollo Endosurgery Stock Price, Forecast & News

$1.43
-0.07 (-4.67 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.38
Now: $1.43
$1.50
50-Day Range
$1.38
MA: $1.60
$1.88
52-Week Range
$1.24
Now: $1.43
$3.79
Volume1,407 shs
Average Volume21,069 shs
Market Capitalization$33.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Read More
Apollo Endosurgery logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.07 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APEN
CUSIPN/A
Phone512-279-5100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$50.71 million
Book Value($0.45) per share

Profitability

Net Income$-27,430,000.00

Miscellaneous

Employees215
Market Cap$33.86 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$1.43
-0.07 (-4.67 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APEN News and Ratings via Email

Sign-up to receive the latest news and ratings for APEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions

How has Apollo Endosurgery's stock price been impacted by COVID-19?

Apollo Endosurgery's stock was trading at $2.0650 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APEN stock has decreased by 30.8% and is now trading at $1.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Apollo Endosurgery?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Apollo Endosurgery
.

When is Apollo Endosurgery's next earnings date?

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Apollo Endosurgery
.

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery Inc (NASDAQ:APEN) announced its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.03. Apollo Endosurgery had a negative return on equity of 565.93% and a negative net margin of 81.70%.
View Apollo Endosurgery's earnings history
.

What price target have analysts set for APEN?

1 analysts have issued twelve-month target prices for Apollo Endosurgery's stock. Their forecasts range from $2.00 to $2.00. On average, they anticipate Apollo Endosurgery's stock price to reach $2.00 in the next year. This suggests a possible upside of 39.9% from the stock's current price.
View analysts' price targets for Apollo Endosurgery
.

Has Apollo Endosurgery been receiving favorable news coverage?

News headlines about APEN stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Apollo Endosurgery earned a coverage optimism score of 0.6 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about Apollo Endosurgery
.

Are investors shorting Apollo Endosurgery?

Apollo Endosurgery saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 437,400 shares, an increase of 145.9% from the April 30th total of 177,900 shares. Based on an average trading volume of 12,300 shares, the short-interest ratio is currently 35.6 days. Approximately 3.6% of the shares of the company are sold short.
View Apollo Endosurgery's Short Interest
.

Who are some of Apollo Endosurgery's key competitors?

What other stocks do shareholders of Apollo Endosurgery own?

Who are Apollo Endosurgery's key executives?

Apollo Endosurgery's management team includes the following people:
  • Mr. Todd Newton, CEO & Director (Age 56)
  • Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
  • Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
  • Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
  • Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Who are Apollo Endosurgery's major shareholders?

Apollo Endosurgery's stock is owned by a variety of retail and institutional investors. Top institutional investors include Gagnon Securities LLC (4.02%), Prosight Management LP (1.60%), Goldman Sachs Group Inc. (1.30%) and University of Texas Texas AM Investment Managment Co. (1.32%). Company insiders that own Apollo Endosurgery stock include R Kent Mcgaughy Jr, Stonepine Capital, LP and Todd Newton.
View institutional ownership trends for Apollo Endosurgery
.

Which institutional investors are selling Apollo Endosurgery stock?

APEN stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC.
View insider buying and selling activity for Apollo Endosurgery
.

Which institutional investors are buying Apollo Endosurgery stock?

APEN stock was bought by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co., Goldman Sachs Group Inc., and Prosight Management LP. Company insiders that have bought Apollo Endosurgery stock in the last two years include R Kent Mcgaughy Jr, Stonepine Capital, LP, and Todd Newton.
View insider buying and selling activity for Apollo Endosurgery
.

How do I buy shares of Apollo Endosurgery?

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $1.43.

How big of a company is Apollo Endosurgery?

Apollo Endosurgery has a market capitalization of $33.86 million and generates $50.71 million in revenue each year. The biotechnology company earns $-27,430,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe.

What is Apollo Endosurgery's official website?

The official website for Apollo Endosurgery is www.apolloendo.com.

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.